Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities
Open Access
- 1 July 2013
- journal article
- review article
- Published by Taylor & Francis Ltd in ImmunoTargets and Therapy
- Vol. 2, 73-90
- https://doi.org/10.2147/ITT.S31426
Abstract
Peer reviewed article authored by (Graves A, Hessamodini H, Wong G,Lim WH). Read article or submit your manuscript for publishing.Keywords
This publication has 100 references indexed in Scilit:
- MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapyInternational Immunopharmacology, 2011
- Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trialBritish Journal of Cancer, 2011
- Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinomaCancer Immunology, Immunotherapy, 2011
- Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccinesBritish Journal of Cancer, 2011
- Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinomaNature, 2011
- Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trialThe Lancet, 2010
- Innovations and challenges in renal cancer: Summary statement from the Third Cambridge ConferenceCancer, 2009
- Predictors of Survival of Advanced Renal Cell Carcinoma: Long-Term Results From Southwest Oncology Group Trial S8949Journal of Urology, 2009
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Cross-priming of CD8+ T cells stimulated by virus-induced type I interferonNature Immunology, 2003